cliexa-RA rated as one of the top 19 RA apps out of more than 900 tested

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

PR.com Official Press Release

Denver, CO, May 02, 2017 –(PR.com)– cliexa-RA, cliexa™’s rheumatoid arthritis app, has been scored among the 19 best RA apps selected from 700+ apps to NIH research:

//www.ncbi.nlm.nih.gov/pmc/articles/PMC5340922/

The review highlights which apps weigh ACR/EULAR treatment guidelines and which include DAS28, among other important features. Researchers rank the apps using the Mobile Application Rating Scale (MARS). A scientific review of mobile apps for tracking rheumatoid arthritis disease activity finds that most apps are either simple calculators for physicians to measure disease activity or tools for patients to track symptoms, most of which do not uniformly collect data using validated instruments or composite disease activity measures.

cliexa’s Co-Founder and CEO Mehmet Kazgan says “cliexa™ changes doctor and patient behavior by connecting patients, clinicians and insurers to better care for and manage chronic conditions which translates into significant cost savings, a better doctor and patient experiences and better outcomes yielding higher customer defined value.” RA Medical Director of cliexa, Dr. Spencer stated that, “In today’s demanding medical environment physicians have limited time to gather relevant data, much less calculate an activity index. With an easily used technology application, patients can be instrumental in helping their doctors determine their disease activity, which, in turn, can lead to better informed treatment decisions. With cliexa-RA we are offering a free mobile application to achieve this goal.”

About cliexa
cliexa staff consists of executive healthcare professionals, physicians, scientists and technologists. cliexa’s first mobile platform, cliexa-RA for Rheumatoid Arthritis has been released to Apple Store in January 2016 and since then, cliexa has developed 3 disease tracking applications, both in iOS and Android platform for Rheumatoid Arthritis (cliexa-RA), Inflammatory Bowel Diseases (cliexa-IBD) and Chronic Obstructive Pulmonary Disease (cliexa-OPD). In November 2016, cliexa has partnered with nation’s biggest payor and provider to run a clinical study with cliexa-RA and raised more than $500K. cliexa platform is a SaaS model offered to end users, clinics, payors and pharma companies for tracking chronic disease symptoms and analytics.

Subscribe To Our Newsletter

More To Explore

Gender Equity in Global Health
News

An Update to Global Health Going Digital

Back in January of 2020, our own Director of Product, Ashley Darnell, shared about her experience and recent manuscript publication with FHI360’s Alive and Thrive

MATTER Health, An Ecosystem for Healthcare Innovation
News

cliexa Becomes Global Member of MATTER

As of June 2020, we are excited to become a global member of the MATTER Health Community, as a company actively working to accelerate healthcare